Nkarta, Inc. NKTX · Stock Open Nkarta, Inc. in new tab
Nkarta, Inc. Analysis (NKTX)
Is Nkarta, Inc. a good investment? Nkarta, Inc. (NKTX) is currently trading at 2.15 USD. Market analysts have a consensus price target of 11.33 USD. This suggests a potential upside from current levels.
Earnings Schedule: Nkarta, Inc. is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -1.65.
Investor FAQ
Does Nkarta, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Nkarta, Inc.?
Nkarta, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -1.34.
Company Profile
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Community Discussion